WO2022216256A2 - Coquille d'oeuf et membrane de coquille d'oeuf contenant un vernis dentaire - Google Patents
Coquille d'oeuf et membrane de coquille d'oeuf contenant un vernis dentaire Download PDFInfo
- Publication number
- WO2022216256A2 WO2022216256A2 PCT/TR2022/050250 TR2022050250W WO2022216256A2 WO 2022216256 A2 WO2022216256 A2 WO 2022216256A2 TR 2022050250 W TR2022050250 W TR 2022050250W WO 2022216256 A2 WO2022216256 A2 WO 2022216256A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eggshell
- membrane
- stmp
- dental
- adsorbed
- Prior art date
Links
- 210000003278 egg shell Anatomy 0.000 title claims abstract description 49
- 108010000912 Egg Proteins Proteins 0.000 title claims abstract description 48
- 102000002322 Egg Proteins Human genes 0.000 title claims abstract description 48
- 239000002966 varnish Substances 0.000 title claims abstract description 41
- 239000012528 membrane Substances 0.000 title claims description 32
- 208000002925 dental caries Diseases 0.000 claims abstract description 29
- 229940012466 egg shell membrane Drugs 0.000 claims abstract description 24
- 210000003298 dental enamel Anatomy 0.000 claims abstract description 20
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 15
- 238000011161 development Methods 0.000 claims abstract description 12
- 230000018109 developmental process Effects 0.000 claims abstract description 12
- 230000003902 lesion Effects 0.000 claims abstract description 11
- 230000009885 systemic effect Effects 0.000 claims abstract description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 5
- 230000004936 stimulating effect Effects 0.000 claims abstract description 5
- 230000036228 toxication Effects 0.000 claims abstract description 5
- 208000034619 Gingival inflammation Diseases 0.000 claims abstract description 4
- 230000011514 reflex Effects 0.000 claims abstract description 4
- 230000008929 regeneration Effects 0.000 claims abstract description 4
- 238000011069 regeneration method Methods 0.000 claims abstract description 4
- 102000008186 Collagen Human genes 0.000 claims description 34
- 108010035532 Collagen Proteins 0.000 claims description 34
- 229920001436 collagen Polymers 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 239000000835 fiber Substances 0.000 claims description 10
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 108010091212 pepstatin Proteins 0.000 claims description 2
- 229950000964 pepstatin Drugs 0.000 claims description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims description 2
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 2
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 2
- 210000004379 membrane Anatomy 0.000 description 30
- 210000004268 dentin Anatomy 0.000 description 24
- 239000000126 substance Substances 0.000 description 23
- 150000002500 ions Chemical class 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 18
- 239000013078 crystal Substances 0.000 description 16
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 15
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 14
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000002328 demineralizing effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 238000005115 demineralization Methods 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 9
- 102000016943 Muramidase Human genes 0.000 description 8
- 108010014251 Muramidase Proteins 0.000 description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 230000033558 biomineral tissue development Effects 0.000 description 8
- 239000001506 calcium phosphate Substances 0.000 description 8
- 229960000274 lysozyme Drugs 0.000 description 8
- 235000010335 lysozyme Nutrition 0.000 description 8
- 239000004325 lysozyme Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000000998 shell membrane Anatomy 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 102100022375 Dentin matrix acidic phosphoprotein 1 Human genes 0.000 description 7
- 101710105839 Dentin matrix acidic phosphoprotein 1 Proteins 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 7
- 230000003592 biomimetic effect Effects 0.000 description 7
- 208000004042 dental fluorosis Diseases 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- -1 viscosity increasers Substances 0.000 description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- 229910052586 apatite Inorganic materials 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011775 sodium fluoride Substances 0.000 description 6
- 235000013024 sodium fluoride Nutrition 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010081689 Osteopontin Proteins 0.000 description 5
- 102000004264 Osteopontin Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000005313 bioactive glass Substances 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000000378 calcium silicate Substances 0.000 description 5
- 229910052918 calcium silicate Inorganic materials 0.000 description 5
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 229920000962 poly(amidoamine) Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000606 toothpaste Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002567 Chondroitin Polymers 0.000 description 4
- 108010026206 Conalbumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 4
- 229960003067 cystine Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 description 4
- 229940078499 tricalcium phosphate Drugs 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 206010016818 Fluorosis Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 3
- 239000004568 cement Substances 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 201000002170 dentin sensitivity Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 2
- ATSBFAGKFWTGFG-UWVGGRQHSA-N 5'-(N(6)-L-lysine)-L-tyrosylquinone Chemical compound OC(=O)[C@@H](N)CCCCNC1=CC(=O)C(=O)C=C1C[C@H](N)C(O)=O ATSBFAGKFWTGFG-UWVGGRQHSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 240000001817 Cereus hexagonus Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000003780 Clusterin Human genes 0.000 description 2
- 108090000197 Clusterin Proteins 0.000 description 2
- 102000030746 Collagen Type X Human genes 0.000 description 2
- 108010022510 Collagen Type X Proteins 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- 108050002883 beta-defensin Proteins 0.000 description 2
- 102000012265 beta-defensin Human genes 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 239000005548 dental material Substances 0.000 description 2
- 230000013847 dentin mineralization Effects 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229910052587 fluorapatite Inorganic materials 0.000 description 2
- 229940077441 fluorapatite Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 2
- 108010034285 ovocalyxin 32 Proteins 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- RSYSVNVHLXTDIR-ZZMNMWMASA-L (2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate;manganese(2+) Chemical compound [Mn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] RSYSVNVHLXTDIR-ZZMNMWMASA-L 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100021523 BPI fold-containing family A member 1 Human genes 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 101000899089 Homo sapiens BPI fold-containing family A member 1 Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001798 Nonvital Tooth Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 102100030194 UPF0690 protein C1orf52 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 230000027632 eggshell formation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 108010071539 ovocleidin 17 Proteins 0.000 description 1
- 108010079283 ovocleidin-116 Proteins 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 208000008655 root caries Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
- A61K6/74—Fillers comprising phosphorus-containing compounds
Definitions
- the invention is related to a florine-free dental varnish, which is applied on the tooth surface to prevent development and progress of dental caries in demineralised enamel, on the other hand contributing alleviaton of gingival inflammations and regeneration of gingival lesions, not stimulating gag and split reflex with its aroma, hardening soon after appliying to the tooth surface, not causing allergic reactions and systemic or local toxications, not containing florine, containing micronized eggshell powder and tri-sodium tri-metaphosphate adsorbed eggshell membrane.
- a dental caries begins with decay of the dental hard tissues by diffusing and demineralizing the mineralised matrix by organic acids resulted in bacterial metabolism. Development of the dental caries is a process that resulted in many demineralization-remineralization cycles. The development period of a dental caries is a process that occurs as a result of many demineralization-remineralization cycles.
- Demineralization is arisen from the loss of calcium (Ca +2 ) ions, phosphate (P04 3 ) ions and other ions from the tooth under the influence of pathological factors that cause the dissolution of hydroxyapatite crystals.
- the most important cause of demineralization of tooth enamel is decreasing the pH of the environment below the dissolution threshold of hydroxyapatite.
- the progression or regression of dental caries depends on the critical balance between demineralization and remineralization processes in the tooth. It is very important for healthy teeth to maintain this balance, which is determined by the concentrations of Ca +2 and P04 3 ions in the saliva as well as the usable F _1 ion concentration in the environment, which ensures the formation of an undamaged enamel surface. Remineralization occurs when Ca +2 , P04 3 and F _1 ions form hydroxyapatite and fluorapatite crystals on the tooth enamel surface and lesion area at critical ambient pH. Mineral loss in incipient caries is inversely proportional to the saturation of the environment with Ca +2 and P04 -3 ions and ambient pH. The pH range for maintaining the remineralization and demineralization balance is 4.5-5.1 and prominent surface layers form in this range, while surface layers do not form around pH 6.0.
- Remineralization applications which are performed at the initial stage of caries development, have received increasing attention in recent years as a non-invasive treatment with accepted therapeutic importance, and for this purpose, it is aimed to introduce many formulations with different efficacy levels.
- Nano-sized n-HAP particles are morphologically and structurally similar to enamel hydroxyapatite. n-HAp is considered a biocompatible and bioactive substance. n-HAP, which was added to toothpastes and mouthwashes in many studies conducted in recent years, is thought to have a remineralization potential in initial caries lesions.
- Nano-p-tricalcum phosphate (h-b-TCP) h-b-TCP is a substance that has the potential to be used for remineralization. It has been shown that the elastic modulus and mineral density of dentin after remineralization in tooth samples immersed in h-b-TCP solution are higher than those immersed in hydroxyapatite.
- ACP Amorphous calcium phosphate
- ACP is the initial solid phase that precipitates in a supersaturated calcium phosphate solution. Since it can easily transform into stable crystalline phases such as octacalcium phosphate or apatitic products, it is thought to play a role as a temporary phase in the formation of apatite in biomineralization.
- the dentin surface is completely covered with hydroxyapatite crystals formed as a result of the application of calcium phosphate loaded agarose gel, and the dentin tubules are obstracted.
- Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)
- the casein phosphopeptide in the CPP-ACP complex can provide calcium and phosphate ions necessary for the remineralization of the hard tissues of the tooth by stabilizing the amorphous ACP with its phosphoserine extensions.
- CPP-ACP prevents demineralization on the healthy dentin surface and increases remineralization in artificial caries lesions created in dentin.
- Ca2Si04 cements traditionally called mineral trioxide aggregate (MTA) are Portland derivative cements.
- Ca2Si04 cements are the materials with bioactive behavior that promote the formation of apatite-containing tissues by releasing Ca +2 and OH 1 ions into the surrounding fluids in a short induction period. Therefore, the Ca2Si04 containing materials are used in the remineralization of demineralized dentin.
- PAA Polyacrylic acid
- DMP-1 Dentin Matrix Protein-1
- PVPA forms analogs of DMPs, inhibits the activity of matrix metalloproteinases, binds ACP nanoprecursors to the collagen matrix and enables DMP-1 to bind to collagen.
- PAMAM-NH2 The PAMAM with amine-terminal
- PAMAM-NH2 Polyhydroxy- terminal PAMAM
- PAMAM-OH Polyhydroxy- terminal PAMAM
- PAMAM- COOH carboxy-terminal PAMAM
- Agarose is a polyanionic polysaccharide containing repeating monomer units.
- the anionic groups of agarose bind to the positively charged groups of collagen, allowing the growth of hydroxyapatite crystals.
- it facilitates the transport of Ca +2 and PO4 3 ions to the dentin surface and the formation of hydroxyapatite crystals through directed ion diffusion.
- the A-HG system also occludes open dentinal tubules and covers the remineralized dentin surface with an enamel-like tissue. Thus, it can reconstruct the microstructure of dentin.
- L-GA has effects such as initiating and promoting remineralization, replacing DMP-1 with these substance-rich areas.
- the remineralized dentin layer which is formed by the common effect of PAA and L-GA, has the same properties as natural dentin.
- DMP-1 Dentin matrix protein-1
- DMP-1 is a noncollagenous protein that largely regulates biomineralization in the dentin matrix. It stabilizes the Ca +2 and PO4 3 ions in the microenvironment by forming the precursor structures required for remineralization. In addition, ACP nanoparticles settle in the intrafiberlar region of the collagen and form apatite crystals in this region. It ensures crystal growth in the intrafiberlary spaces, increases the mechanical properties of dentin, and protects collagen from enzymatic and acidic destructions. A6.7. Phosphorylated chitosan (P-chi)
- Phosphorylated chitosan which used in the biomimetic remineralization of dentin, has functions such as initiating remineralization and binding to collagen fibers and introducing the functional groups on it.
- bioactive glasses are materials that have the potential to be used for remineralization in dentistry.
- FHA-G Fluorohydroxyapatite gel
- FHA gel system contains calcium nitrate (Ca(N03)2), potassium dihydrogen phosphate (KH2PO4), potassium fluoride (KF), deionized water and agarose. It is widely accepted that FFIA-G can form apatite structures on dentin in deep caries and encourage remineralization by diffusion of Ca +2 and PO4 '3 ions from A-FIG towards the dentin surface.
- the most important ones of the main functional substances used in the preparation of traditional dental varnishes containing fluorine are the substances that act as a source of Ca +2 and PO4 '3 ions to be used in the remineralization area, and excipients substances including water, thickeners, viscosity increasers, pH buffers, sweeteners and flavorings.
- DCP di-calcium phosphate
- TCP tri calcium phosphate
- BAG bioactive glass
- F is the main functional component of conventional dental varnishes.
- F has been used for 50 years as milk additive, salt, oral cleaning products and food supplements as local and systemic applications in order to prevent the formation and progression of dental caries.
- this practice has been currently terminated in many countries since systemic toxications have emerged.
- oral care products such as F-containing toothpastes, gels, mouthwashes have been prepared for this purpose.
- F is also used to reduce dentin sensitivity. Fluorinated dental varnishes have been developed to increase the contact time of F with the tooth, thereby enhancing the penetration of the enamel into the surface layers.
- the application of fluoride tooth varnish to 5-year-old-children has widely been used.
- the app is also carried out in the disabled and weak people who are bedridden.
- the fluorine tooth varnishes which are used for this purpose, contain about 5% topical fluoride (NaF) that a level relatively higher than those of toothpastes and and mouthwashes.
- This application might increase F ratio of environment of the enamel surface up to 77%.
- the producers recommend keeping away from foods and beverages for first 30 minutes and from hot and hard foodstuffs in the following 4 hours, not to brush teeth during the application day, and to start regular toothbrush at the day after. It is also recommended that the aplication should be repeated every 6 months.
- the main content of fluorine varnishes is 5% NaF.
- fluorine tooth varnish contributes to the formation of good quality enamel that is resistant to caries by ensuring the healthy development and well mineralization of the enamel layer of the developing tooth.
- Topically applied F also replaces the OFF 1 ions in the hydroxyapatite crystal to form florapatite. It is accepted that fluorapatite is more difficult to dissolve and prevents the formation of acid in the microbial dental plaque on the tooth surface, preventing the dissolution of hydroxyapatite in the enamel and as a result supporting the remineralization of enamel.
- Dental fluorosis which displays an increasing incidence, leads to mild to severe esthetic disorders and mineral substance losses in the teeth and requires restorative or prosthetic treatment.
- acute fluoride toxicity may also develop, especially if large amount of the gel is swallowed.
- the acute toxic dose of NaF is 5 mg/kg
- 50 mg of NaF is the amount required for the occurence of acute toxic symptoms for a 10 kg child.
- a toxic dose can be reached if a child of this weight swallows 4 ml of dental gel.
- NaF used in oral care products has some allergic- immunological effects.
- NaF can cause harmful effects not only on the oral mucosa, but also by reacting with hydrochloric acid in the stomach to form corrosive and non- dissociated hydrofluoric acid (HF). This acid also damages the gastro-duodenal mucosa.
- Dental varnishes are coating materials in gel form that are applied as a thin layer on demineralized tooth surfaces with the help of a brush. Dental varnishes also contain hardener, thickener, flavoring agents and solvents.
- the composition of dental varnish includes resins and thickeners. Hydrolysed-resin and partially hydrolyzed-resins are most preferred resins. Carboxy methylcellulose (CMC) and xanthan gum (Xsantan gum) are added to the formula as thickeners. Resin and thickeners provide film formation and mechanical stability on the tooth surface, and realize the controlled release of the functional substances of the varnish to the tooth surface.
- CMC Carboxy methylcellulose
- Xsantan gum xanthan gum
- Solvents are also added into the dental varnish as a phase to increase the wettability of the surface, to guarantee the homogeneous mixing of the components and to carry the other components of the varnish.
- the most commonly used solvent is ethyl alcohol.
- Polyethylene glycol (PEG) is also added to dental varnishes in required amounts due to its high solubility and thickening properties.
- NaHC03 sodium bicarbonate
- the subject of the invention is related to dental varnish which the main components are micronized egg shell powder and sodium tri-metaphosphate (STMP) adsorbed egg shell membrane.
- STMP sodium tri-metaphosphate
- the eggshell mainly consists of calcium carbonate as the mineral part of the egg shell (98.4%).
- the shell contains 0.8% of calcium carbonate nad 0.8% of tricalcium phosphate (TCP).
- TCP tricalcium phosphate
- Approximately 0.64% of the shell is protein, 1.7% is water and 0.03% is lipid.
- Eggshell has a high rate (380 mg/g) of strontium (Sr). Sr has an anabolic effect on the human bone metabolism and strengthens the enamel layer of the teeth.
- F, Cu and Se which are the other elements found in the eggshell, also have an positive effect on the bone metabolism.
- the chicken eggshell contain a large number of bioactive molecules.
- bioactive substances found in eggshell extracts that play important roles are ovotransferrin, ovocleidin-17, ovocleidin-116, osteopontin (OPN), ovalbumin, ovocalyxin-21, ovocalyxin-25, ovocalyxin-32, ovocalyxin- 37, clusterin and lysozyme.
- OPN which is one of the matrix proteins in the eggshell, is a phosphorylated glycoprotein and is highly found in the bone and kidney. OPN has very important roles in bone modeling and remodeling.
- Clusterin is also is an other molecule found in the eggshell matrix in 2003 and it is possibly synthesized under stress conditions and acts as a chaperon that plays a role in preventing precipitation and gaining structural stabilization of proteins.
- GAG Glucosaminoglycans
- the GAGs are anionic polysaccharides formed by the end-to-end binding of disaccharide molecules formed by hexosamine and uronic acid. The majority of GAGs are bound to core proteins to form proteoglycans.
- the GAGs obtained from the chicken eggshell are composed of 48% of the hyaluronic acid and 52% of galactosaminoglycans (GAAG).
- GAAGs are the GAGs haning the most chondroitin sulfate-dermatan sulfate copolymers.
- Ovoglycan consisting of a dermatan sulfate chain, is a polyanionic GAG.
- Keratan sulfate one of the GAGs found in the eggshell, plays a role in the nucleation stage of crystal formation. It shows high calcium affinity and regulates crystal growth.
- Cell differentiation and proliferation factor-1 (transforming growth factor-1 , TGF-1 ), calcitonin and progesterone were also detected in low amounts in the eggshell.
- Eggshell matrix protein fraction contains potential antimicrobial proteins such as histones and b-defensins. Eggshells also contain significant substances that have a bacteriostatic effect on Gram-negative bacteria, E. Coli D31 and P. Aeruginosa. These antibacterial agents prevent the growth of Gram + bacteria, B. subtilis and S. aureus. This effect is due to lysozyme in the cuticle and protein extracts of the outer eggshell. Lysozyme is an enzyme with a length of 129 amino acids, 14.4 kDa that breaks down bacterial cell walls.
- lysozyme In addition to its antimicrobial effect, lysozyme also plays an important role during eggshell formation, since it determines the morphology of calcite crystals in the CaC03 structure.
- the organic matrix of the egg white and eggshell also contains large amount of the lysozyme.
- lysozyme can be used in oral care products such as toothpaste and mouthwash, to protect against bacteria that cause periodontitis and to protect against oral mucosal infections. Oral and topical application of lysozyme has been found to be effective in protection from herpes simplex virus and against HIV.
- P. Aureginosa, B. Cereus, and S. Aureus are strongly inhibited when 100 pg/mL of soluble eggshell matrix protein is present in the environment.
- E. coli and S. Enteritidis are weakly inhibited after treatment for up to 4 hours. These proteins show their effects by breaking down the bacterial cell membrane.
- transferrins in the eggshell There are also transferrins in the eggshell.
- ovotransferrin is antibacterial because it binds iron in the medium at concentrations of 1 mg/ml or higher.
- Ovotransferrin which is located close to the pores in the eggshell, shows its antibacterial effect its location.
- Ovocalyxin-32 is another antibacterial agent found in the cuticle and outer layers of the eggshell. It inhibits the proliferation of B. subtilisin and also has carboxypeptidase inhibitory activity.
- Ovocalyxin-36 is also another protein found in the eggshell matrix. This protein has similarities with lipopolysaccharide-binding proteins, which increase bacterial membrane permeability, and with members of the PLUNC protein family, which serve as a defense in the eggshell.
- Potential antimicrobial proteins such as histones and chicken beta-defensins of the acid-soluble eggshell matrix protein fraction were found to be effective against P. Aeruginosa, B. Cereus and S. Aureus.
- micronized eggshell powder prepared under suitable conditions can support remineralization positively by preventing the development of infection with the bioactive substances it contains, as well as providing the Ca+2 ions necessary for the remineralization of the caries area, with its high CaC03 content.
- the membranes are composed of 70% of organic materials, 10% of inorganic materials, and 20% of water.
- the membranes contain 16% of nitrogen, 2% of saccharides, and 1.35-1.40% of lipids.
- the ratio of neutral lipids to complex lipids is 86:14.
- 63% is sphingomyelin and 12% is phosphatidylcholine.
- the membranes consist of a filamentous protein network that is insoluble in water. Membrane proteins in filamentous form provide the membrane with semi-permeable properties.
- the shell membranes contain a significant amount of cystine, and since 5- hydroxylysine is also present, they contain a significant amount of collagen.
- the filamentous elements of the inner and outer subshell membranes are mostly composed of Type-I, Type-V and Type-X collagen.
- Desmosine, isodesmosine, and a non-elastin protein also exist as a cross linker protein in the shell membranes.
- the egg shell membrane contains 5-10% hyaluronic acid by weight basis.
- the membrane contains 2-5% w/w (w/w) of hexosamine, 0.3-3.0% (w/w) of chondroitin and 5-30% (w/w) of collagen.
- the collagen ratio was found to be 35% by wet weight basis, when based on the 4.5% hydroxyproline amino acid content.
- the most abundant collagen is Type-I collagen; there are also Type-V and Type-X collagens to a lesser extent.
- Type-X collagen is known as the collagen that controls tissue mineralization. Glucosamine ratio was 5- 10% and chondroitin ratio was determined as 9% by wet weight basis.
- the eggshell membranes contain high levels of arginine, glutamic acid, methionine, histidine, cystine and proline amino acids. At the same time, hydroxy proline, hydroxylysine and desmosine amino acids are also abundant. Cystine is a sulfur-containing amino acid that is essential for healthy skin, hair, bone and connective tissue. There is plenty of cystine in the structure of the alpha-keratin protein, which forms the nail, hair and skin tissues and is also found in the oral mucosa. Cysteine takes part in the formation of collagen-containing tissues and increases the elasticity of the skin. Cysteine supplementation accelerates the healing of burns and other types of wounds, increases the flexibility of the joints in arthiritis.
- the eggshell membranes also contain bacteriolytic enzymes such as N-acetyl glucosaminidase. Some components in the membrane reduce the resistance (thermal resistance) of Gram-positive and Gram-negative pathogenic bacteria (S. Enteritis, E. Coli 0157 : H7, L. Monocytogenes and S. Aureus) to high temperatures.
- the shell membranes also contain acidic GAGs. Of these, dermatan sulfate and chondroitin sulfate are the most important.
- the membranes also contain sulfated glycoproteins. Glycoproteins include hexosamine, hexose and fucose.
- ovotransferrin desmosine and isodesmosine
- lysyl oxidase lysozyme
- Oral and injectable preparations containing GAGs in the eggshell membrane, chondroitin sulfate, hydrolyzed or natural forms of collagen, sodium hyaluronate, manganese ascorbate chelate and L- malic acid are used in the prevention and treatment of connective tissue and skin diseases.
- the composition containing these substances contributes positively to wound healing by accelerating the synthesis activity of chondrocytes and is effective in maintaining tissue health.
- preparations containing collagen and GAG suspensions for topical use are also used. For this reason, the use of eggshell membrane and/or its components in pulp and tissue lesions around the teeth may provide significant benefits.
- the eggshell membrane also contains the enzyme lysyl oxidase, a copper- containing amine oxidase with the quinocofactor lysine tyrosylquinone (LTQ) in its active site.
- This enzyme plays important roles in the development and repair of connective tissue. In case of dietary copper deficiency, connective tissue damage occurs in the gingival tissue, as in other regions. For this reason, the presence of eggshell membrane and/or its components in the dental material to be used in oral care products and in the closure of the contact area of endodontically treated teeth may contribute to the repair of the damaged area and maintaining its healthy condition.
- BSE bovine spongious encephalopathy
- Eggshell and shell membranes and their products do not contain animal tissue and most importantly genetic material. Since the eggshell membrane is the only biological material that does not contain DNA, its antigenicity is low and it is less likely to cause allergic reactions. Therefore, eggshell powder and eggshell membrane or their products have ideal properties that can be used in the preparation of dental materials. Because that eggshell and shell membranes are easy to obtain and rich in antibacterial proteins, they have a strong potential for use in the field of health.
- Stmp binds to the demineralized collagen matrix by providing phosphorylation of soluble type i collagen by forming covalent bonds between the phosphate group and hydroxyl or amino groups in alkaline conditions, and allows the collection of acp nanoprecursors at the remineralization site. This event ensures the attachment of phosphate groups to the collagen membrane. Phosphate groups on the phosphorylated type i collagen trap calcium ions, by lowering the surface energy required for the transition to the crystalline phase, making them preferred nucleation centers the resulting mineralization is heterogeneous, and the formed crystal structure is initially octa-calcium phosphate, and this molecule subsequently transforms into the more stable hydroxyapatite.
- the collagen membrane surface treated with stmp acts as a nucleation center that triggers mineralization by this mechanism, the surface of type i collagen treated with stmp is mineralized.
- This phenomenon is a strategy that mimics biomimetic remineralization to induce directed growth of apatite crystals phosphate groups of stmp can bind to the surface of collagen fibers at depths of hundreds of micrometers (up to 300 pm) in the caries area.
- MMPs matrix metalloproteinases
- MMPs are the enzymes that are activated in the presence of Ca+2 and Mg+2, removing these ions from the environment inhibits their activities. Therefore, STMP can be applied simultaneously to reduce the destruction of the dentin matrix in dental caries and to provide remineralization. As seen in clinical practice, dentin softens and becomes infected, and disperses in an acid environment. In newly formed caries, this demineralization layer is thick. If this layer can be sufficiently remineralized, preservation of the tooth is possible. STMP is not very effective at nontoxic concentrations of 0.5% or 1% as it is not sufficient to bind all of the Ca+2 ions in the environment.
- the dental varnish After the dental varnish is applied to the tooth, it forms a homogeneous film layer on the tooth surface with the evaporation of the solvent in its content, and when this film layer comes into contact with the saliva, it binds to the area with the help of its resin content.
- Bioactive substances such as Ca+2, P04-3 HC03-1 ions and potential antimicrobial proteins such as type I, type V and type X collagens, histones and beta-defensins, osteopontin, GAGs found in eggshell powder liberated and precipitate into demineralized pores and fissures on the tooth surface, as a result of contact with saliva.
- bioactive substances on the tooth surface initiate remineralization at the demineralization site.
- STMP covalently binds to the NH+3 groups of collagen fibers at a depth of hundreds of micrometers (up to 300 pm), which are exposed in the demineralization area with its phosphate group under alkaline conditions.
- ions such as calcium, phosphate and carbonate, which are the basic components of hydroxycarbonapatite playing a very important role in the remineralization of the tooth and gaining the remineralization area the natural structure of the tooth..
- This phenomenon is a strategy that mimics biomimetic remineralization to induce directed growth of apatite crystals. Since this layer formed at first is very thin, it has an amorphous structure. However, it thickens over time and a hydroxycarbonapatite (HCA) layer is formed, which is chemically and structurally very similar to the mineral composition of the tooth. In this way, open dentin tubules are closed and dentin sensitivity healed, contributing to the repair of the damaged area and maintaining its healthy condition.
- HCA hydroxycarbonapatite
- the invention is related to a florine-free dental varnish, which is applied on the tooth surface to prevent development and progress of dental caries in demineralised enamel, on the other hand contributing alleviaton of gingival inflammations and regeneration of gingival lesions, not stimulating gag and split reflex with its aroma, hardening soon after appliying to the tooth surface, not causing allergic reactions and systemic or local toxications, not containing florine, containing micronized eggshell powder and tri-sodium tri-metaphosphate adsorbed eggshell membrane.
- the eggshells and membranes of the fresh eggs, whose contents are emptied, are separated by an appropriate method and dried separately under 300 mbar vacuum at 50°C overnight.
- the membrane material prepared in item 1 is first mixed in a 5% acetic acid solution for 1 hour, and then kept overnight in ether-acetone (v/v) by shaking every 2 hours, in order to remove remaining calcium salts and oil and oil-soluble residues. After filtration, the membrane pieces are dried in an oven at 50°C overnight.
- the membrane pieces obtained by the method in Item 2 are treated for 48 hours at 37°C, by shaking every 2 hours in 3200 U/mg pepsin prepared with 1% (w/v) 0.5M acetic acid solution for the removal of proteins other than collagen. At the end of the period, the enzymatic activity is inhibited by adding 0.2 mg/100 ml pepstatin to 100 ml.
- the membrane pieces washed with distilled water are treated with 0.2 M STMP at a pH of 11.5 at room temperature for 24 hours to bind phosphate groups to the collagen fibers.
- the filtered membrane pieces are dried in an oven at 50°C overnight and ground into powder. 4. Powdering the eggshell and eggshell membrane particles
- the eggshell pieces prepared in item 1 and the membrane pieces prepared in item 3 are ground to a micronized powder in a suitable grinder where overheating is prevented.
- the prepared products are stored in a dry and cool environment until the dental varnish is prepared.
- Dental varnish is a dental varnish that contains resin that ensures homogeneous spreading on the tooth surface and adhesion of the content to the tooth surface, STMP-adsorbed eggshell membrane and eggshell powder, xylitol as an artificial sweetener and suitable aroma.
- STMP sodium trimetaphosphate
- ethyl alcohol, desired flavoring substance, xylitol as artificial sweetener, sodium fluoride (NaF) are optionally added to the high-speed planetary mixer depending on the amount of tooth varnish to be prepared and mixed thoroughly for half an hour.
- a sufficient amount of resin is added into the mixture and mixed until it completely dissolves.
- PEG poly ethylene glycol
- CMC carboxy methyl cellulose
- Xantan gum are added into the mixture and the mixture is thoroughly mixed in the high-speed planetary mixer.
- the membrane and shell powder obtained by the preparation methods described in Items 3 and 4 is added to the mixture and mixed thoroughly. The amount of membrane powder is adjusted so that it is at least 2% by weight of the total product.
- the final pH of the prepared mixture is adjusted to 9 with sodium bicarbonate and homogenization is ensured by mixing in the mixture at very high speed for 1 more hour.
Landscapes
- Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dental Preparations (AREA)
Abstract
L'invention concerne un vernis dentaire exempt de florine, qui est appliqué sur la surface de la dent pour empêcher le développement et la progression de caries dentaires dans l'émail déminéralisé, et qui contribue par ailleurs à l'atténuation des inflammations gingivales et à la régénération des lésions gingivales, ne stimule pas le réflexe nauséeux et de rejet avec son arôme, durcit rapidement après application sur la surface de la dent, ne provoque pas de réactions allergiques et de toxicité systémique ou locale, ne contient pas de florine, et contient une poudre de coquille d'oeuf micronisée et une membrane de coquille d'oeuf adsorbée par trimétaphosphate de trisodium.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2021/006313A TR202106313A2 (tr) | 2021-04-08 | 2021-04-08 | Yumurta kabuğu ve kabuk zari i̇çeren di̇ş verni̇ği̇ |
TR2021/006313 TR2021006313A2 (tr) | 2021-04-08 | Yumurta kabuğu ve kabuk zari i̇çeren di̇ş verni̇ği̇ |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022216256A2 true WO2022216256A2 (fr) | 2022-10-13 |
WO2022216256A3 WO2022216256A3 (fr) | 2022-11-10 |
Family
ID=83545647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2022/050250 WO2022216256A2 (fr) | 2021-04-08 | 2022-03-21 | Coquille d'oeuf et membrane de coquille d'oeuf contenant un vernis dentaire |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR202106313A2 (fr) |
WO (1) | WO2022216256A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4393468A1 (fr) * | 2022-12-28 | 2024-07-03 | Septodont ou Septodont SAS ou Specialites Septodont | Composition de vernis dentaire anhydre |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007197393A (ja) * | 2006-01-30 | 2007-08-09 | Yukio Hasebe | 歯磨 |
WO2014021797A2 (fr) * | 2012-07-30 | 2014-02-06 | Melek Akman | Matériau de ciment pour renouveler des tissus dentaires endommagés |
-
2021
- 2021-04-08 TR TR2021/006313A patent/TR202106313A2/tr unknown
-
2022
- 2022-03-21 WO PCT/TR2022/050250 patent/WO2022216256A2/fr unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4393468A1 (fr) * | 2022-12-28 | 2024-07-03 | Septodont ou Septodont SAS ou Specialites Septodont | Composition de vernis dentaire anhydre |
WO2024141586A1 (fr) * | 2022-12-28 | 2024-07-04 | Septodont Ou Septodont Sas Ou Spécialités Septodont | Composition de vernis dentaire anhydre |
Also Published As
Publication number | Publication date |
---|---|
TR202106313A2 (tr) | 2021-08-23 |
WO2022216256A3 (fr) | 2022-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4541455B2 (ja) | カルシウムホスホペプチド複合体 | |
JP4746441B2 (ja) | 過飽和溶液中のカルシウムおよびリン酸イオンからなるうがい薬 | |
JP5960593B2 (ja) | マイクロカプセル化組成物及び組織石灰化の方法 | |
US5997301A (en) | Treatment of tooth surfaces and substances therefor | |
Divyapriya et al. | Casein phosphopeptide-amorphous calcium phosphate in dentistry: An update | |
WO2012036645A2 (fr) | Procédé de préparation d'un gel buccal pour hygiène bucco-dentaire contenant de la poudre de coquilles d'œufs | |
Gao et al. | Chitosan-based therapeutic systems and their potentials in treatment of oral diseases | |
EP0758223B1 (fr) | Composition d'hygiene buccale | |
Erpaçal et al. | A general overview of chitosan and its use in dentistry | |
US20220142881A1 (en) | Compositions and methods for promoting mineralization | |
WO2022216256A2 (fr) | Coquille d'oeuf et membrane de coquille d'oeuf contenant un vernis dentaire | |
WO2015009256A1 (fr) | Greffe osseuse à partir de poudre de coquille d'œuf d'autruche et son procédé de préparation | |
Shetty et al. | Applications of chitosan in dentistry | |
TR2021006313A2 (tr) | Yumurta kabuğu ve kabuk zari i̇çeren di̇ş verni̇ği̇ | |
Jindal et al. | Reverse the adverse: A review | |
Acharya et al. | Recent biomimetic advances in rebuilding lost enamel structure | |
RU2535045C1 (ru) | Зубная паста, содержащая стимуляторы регенерации | |
WO2014021797A2 (fr) | Matériau de ciment pour renouveler des tissus dentaires endommagés | |
JPS59152312A (ja) | 口腔組成物 | |
Naji | Materials Used in Remineralization of Initial Caries | |
WO2023048683A1 (fr) | Agent de reminéralisation présentant des propriétés biomimétiques et anti-cariogènes | |
Adiana | The Effectiveness of Chitosan on Children’s Dental and Oral Health as a Primary Preventive: A Literature Review | |
Chauhan et al. | APPLICATIONS OF CHITOSAN IN DENTISTRY-A REVIEW ARTICLE | |
Onwubu et al. | Biobased materials in dentistry | |
Venghat et al. | APPLICATION OF CHITOSAN IN DENTAL HEALTH SCIENCES: A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22785092 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |